Literature DB >> 21252067

Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction.

Yang Liu1, Xiao-Ming Gao, Lu Fang, Nicole L Jennings, Yidan Su, Xu Q, Andre L Samson, Helen Kiriazis, Xin-Feng Wang, Leonard Shan, Sharelle A Sturgeon, Robert L Medcalf, Shaun P Jackson, Anthony M Dart, Xiao-Jun Du.   

Abstract

OBJECTIVE: The goal of this study was to investigate the role of platelets in systemic and cardiac inflammatory responses and the development of postinfarct ventricular complications, as well as the efficacy of antiplatelet interventions. METHODS AND
RESULTS: Using a mouse myocardial infarction (MI) model, we determined platelet accumulation and severity of inflammation within the infarcted myocardium by immunohistochemistry and biochemical assays, analyzed peripheral blood platelet-leukocyte conjugation using flow cytometry, and tested antiplatelet interventions, including thienopyridines and platelet depletion. Platelets accumulated within the infarcted region early post-MI and colocalized with inflammatory cells. MI evoked early increase in circulating platelet-leukocyte conjugation mediated by P-selectin/P-selectin glycoprotein ligand-1. Antiplatelet interventions inhibited platelet-leukocyte conjugation in peripheral blood, inflammatory infiltration, content of matrix metalloproteinases or plasminogen activation, and expression of inflammatory mediators in the infarcted myocardium (all P<0.05) and lowered rupture incidence (P<0.01). Clopidogrel therapy alleviated the extent of chronic ventricular dilatation by serial echocardiography.
CONCLUSIONS: Platelets play a pivotal role in promoting systemic and cardiac inflammatory responses post-MI. Platelets accumulate within the infarcted myocardium, contributing to regional inflammation, ventricular remodeling, and rupture. Antiplatelet therapy reduces the severity of inflammation and risk of post-MI complications, demonstrating a previously unrecognized protective action.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21252067     DOI: 10.1161/ATVBAHA.110.220467

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  P2Y12 Receptor Modulates Sepsis-Induced Inflammation.

Authors:  Elisabetta Liverani; Mario C Rico; Alexander Y Tsygankov; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-04-07       Impact factor: 8.311

Review 2.  The role of P2Y₁₂ receptor and activated platelets during inflammation.

Authors:  Elisabetta Liverani; Laurie E Kilpatrick; Alexander Y Tsygankov; Satya P Kunapuli
Journal:  Curr Drug Targets       Date:  2014       Impact factor: 3.465

Review 3.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

4.  ADP exerts P2Y12 -dependent and P2Y12 -independent effects on primary human T cell responses to stimulation.

Authors:  Harika Vemulapalli; Samara Albayati; Viren C Patwa; Douglas G Tilley; Alexander Y Tsygankov; Elisabetta Liverani
Journal:  J Cell Commun Signal       Date:  2019-12-05       Impact factor: 5.782

5.  Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury.

Authors:  Esther Sok Hwee Cheow; Woo Chin Cheng; Chuen Neng Lee; Dominique de Kleijn; Vitaly Sorokin; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2016-05-27       Impact factor: 5.911

6.  Lung injury during LPS-induced inflammation occurs independently of the receptor P2Y1.

Authors:  Elisabetta Liverani
Journal:  Purinergic Signal       Date:  2016-11-04       Impact factor: 3.765

Review 7.  β-Adrenoceptor activation affects galectin-3 as a biomarker and therapeutic target in heart disease.

Authors:  Xiao-Jun Du; Wei-Bo Zhao; My-Nhan Nguyen; Qun Lu; Helen Kiriazis
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

8.  Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice.

Authors:  Yang Liu; Nicole L Jennings; Anthony M Dart; Xiao-Jun Du
Journal:  World J Exp Med       Date:  2012-04-20

9.  Prasugrel metabolites inhibit neutrophil functions.

Authors:  Elisabetta Liverani; Mario C Rico; Analia E Garcia; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  J Pharmacol Exp Ther       Date:  2012-10-24       Impact factor: 4.030

10.  An 8-year follow-up of a patient with acute myocardial infarction complicated with ventricular rupture and cerebral thrombosis treated conservatively: a cohort study.

Authors:  Xue Li; Lianyou Zhao; Qiangsun Zheng
Journal:  BMJ Case Rep       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.